GLAXO vs Pfizer: share price, P/E, ROE and financials compared
Glaxosmithkline Pharmaceuticals
Pfizer
GLAXO and Pfizer at a glance
GLAXO and Pfizer are both listed in Healthcare. GLAXO is the larger by market cap, at ₹42,772 Cr against ₹17,640 Cr for Pfizer (2.4 times as large). On valuation, Pfizer has the lower P/E (23.2× against 37.3×) and the lower price-to-book (4.02× against 22.73×). On returns and margins, GLAXO has the higher ROCE (55.4% against 22.9%) and the higher ROE (63.9% against 20.9%), while Pfizer has the higher operating margin (36.7% against 34.1%). Over three years, GLAXO has faster 3-year sales growth (+5.7% against +1.3% a year) and faster 3-year profit growth (+19.3% against +5.0% a year). Neither carries much debt for its equity: debt-to-equity is 0.02× for GLAXO and 0.04× for Pfizer.
Key metrics, side by side
| Metric | GLAXOGLAXO | PfizerPFIZER |
|---|---|---|
| Price (₹) | 2,524.80 | 3,856.00 |
| Market cap (₹ Cr) | 42,772 | 17,640 |
| P/E | 37.3× | 23.2× (the lower figure, shaded) |
| P/B | 22.73× | 4.02× (the lower figure, shaded) |
| Dividend yield, trailing | 2.26% (the higher figure, shaded) | 1.95% |
| ROE | 63.9% (the higher figure, shaded) | 20.9% |
| ROCE | 55.4% (the higher figure, shaded) | 22.9% |
| Operating margin (OPM) | 34.1% | 36.7% (the higher figure, shaded) |
| Net margin (NPM) | 27.3% | 32.4% (the higher figure, shaded) |
| Sales CAGR 3Y | +5.7% (the higher figure, shaded) | +1.3% |
| Profit CAGR 3Y | +19.3% (the higher figure, shaded) | +5.0% |
| Debt to equity | 0.02× | 0.04× |
| Interest cover | 515.6× (the higher figure, shaded) | 103.9× |
| Net profit TTM (₹ Cr) | 1,147 | 859 |
| 1Y return | −6.0% (the higher figure, shaded) | −24.6% |
| Promoter holding | 75.00% | 63.92% |
GLAXO vs Pfizer: common questions
Which is bigger, GLAXO or Pfizer?
By market cap, GLAXO is bigger at ₹42,772 Cr, against ₹17,640 Cr for Pfizer (prices as of 6 Nov 2026). Net profit over the last twelve months was ₹1,147 Cr for GLAXO and ₹859 Cr for Pfizer.
Which has a lower P/E ratio, GLAXO or Pfizer?
GLAXO trades at a P/E of 37.3× and Pfizer at 23.2×. Pfizer has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, GLAXO or Pfizer?
GLAXO reports a return on equity of 63.9% and Pfizer 20.9%. GLAXO has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, GLAXO or Pfizer?
Over the last three years: Sales grew +5.7% a year at GLAXO and +1.3% at Pfizer, so GLAXO grew sales faster; profit grew +19.3% a year at GLAXO and +5.0% at Pfizer, so GLAXO grew profit faster. Past growth doesn’t predict future growth.